rct
    2013

    Analysis of Safety from a Human Clinical Trial with Pterostilbene

    Riche DM, McEwen CL, Riche KD, Sherman JJ, Wofford MR, Deschamp D, Griswold M

    Published in Journal of Toxicology

    Key Findings

    Pterostilbene up to 250 mg/day for six to eight weeks was generally well tolerated with no significant differences in adverse events versus placebo.

    Conclusions

    Short-term pterostilbene appears safe at studied doses.

    Limitations

    Short exposure; safety endpoints only; single trial.

    Supplements Studied

    Pterostilbene up to 250 mg/day for six to eight weeks was generally well tolerated with no significant differences in adverse events versus placebo.

    Study Details

    Year:2013
    Sample Size:80
    Duration:8 weeks
    Quality Score:6/10

    Access Study

    View on DOIOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.